Local Medicare Contractors Propose Coverage For Novocure’s Optune
Executive Summary
The Durable Medical Equipment Medicare Administrative Contractors (DME MACs) have issued a proposed local coverage determination that provides coverage of Novocure’s Optune Tumor Treating Fields device for treating newly diagnosed glioblastoma at certain cancer centers.
You may also be interested in...
Novocure Transforms Patient Support System During Pandemic
The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.
Higher Doses Of Novocure’s TTF Help New Glioblastoma Patients
The first reported analysis demonstrating a patient-level dose response with Novocure’s Tumor Treating Fields therapy is now published. The post-hoc analysis of the EF-14 trial showed higher doses of Tumor Treating Fields improved survival in newly diagnosed glioblastoma patients.
Results Recap: Long-Term Results Support NovoCure's Optune Brain-Cancer Technology
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 30 – Dec. 6, includes results of a retrospective post-hoc sub-group analysis of the EF-14 phase III pivotal trial of Novocare's Optune system in newly diagnosed glioblastoma, one-year data from a study of Vieve Medical's Geneveve treatment of mild-to-moderate stress urinary incontinence, and complete results from the Long-Term Treatment Study of NeuroPace's RNS system to treat epileptic seizures.